Pharmaceutical Technology20 天
Zanubrutinib by BeiGene for Lupus Nephritis: Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...
Pharmaceutical Technology20 天
Axatilimab by Incyte for Solid Tumor: Likelihood of Approval
Axatilimab is under clinical development by Incyte and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...